ArticleGland surgery2025
Development and validation of a screening model for benign and malignant breast masses based on S-Detect and microvascular flow imaging.
Article in Gland surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Imaging examination of a breast mass is essential for improving breast cancer detection. Previous screening models of benign and malignant breast masses demonstrated a high level of subjectivity due to the inability to conduct quantitative evaluations. Thus, this study aimed to construct an objective, convenient, and effective nomogram incorporating S-Detect and microvascular flow imaging (MVFI) to predict breast cancer risk. Methods: Female patients with breast masses detected by conventional ultrasound examinations at the Second Affiliated Hospital of Anhui Medical University between January 2021 and October 2024 were retrospectively analyzed. All patients underwent preoperative assessments with both S-Detect and MVFI. The pathological results served as the gold standard for diagnosis. After screening, a total of 724 breast masses from 712 patients were randomized into the training (506 masses) and validation (218 masses) groups. Univariate analysis assessed patient age, as well as the location, size, vascular index (VI), and S-Detect-based diagnosis of the masses. Risk factors for predicting breast cancer were screened using multivariate analysis. A nomogram prediction model was then constructed. Diagnostic performance, clinical utilization value, and calibration were determined using the receiver operating characteristic (ROC) curve, decision curve analysis (DCA), and calibration curve, respectively. Nomogram risk was calculated for each breast mass for risk stratification. Results: The training group included 208 benign and 298 malignant masses, while the validation group comprised 85 benign and 133 malignant masses. Multivariate analysis demonstrated that mass size [odds ratio (OR) =1.08; P<0.001], age (OR =1.09; P<0.001), VI (OR =1.07; P<0.001), and S-Detect-based diagnosis (OR =28.37; P<0.001) were risk factors for predicting breast cancer. The area under the curve (AUC) for the nomogram model was significantly greater than that for S-Detect in both the training (0.93 Conclusions: This novel nomogram model based on quantitative and objective ultrasound and clinical features can quantify the malignancy risk of breast masses, identify high-risk individuals, and provide a reference for further examinations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.